WuXi AppTec Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition in the CRDMO Industry
WuXi AppTec sets new benchmarks in strategic execution and technological advancement, further…
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating…